Exelixis, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2023, compared with the three months ended March 31, 2022. The request metadata identifies 2022 Q1, but the supplied filing is for 2023 Q1. Amounts below are in U.S. dollars.
Business context and financial performance
Exelixis is an oncology company with four marketed products. CABOMETYX and other cabozantinib-related sales account for most revenue. The company reports one operating segment.
| Metric | Q1 2023 | Q1 2022 | Change/comment |
|---|---|---|---|
| Total revenue | $408.8 million | $356.0 million | Up 15% |
| Net product revenue | $363.4 million | $310.3 million | Up 17% |
| CABOMETYX revenue | $361.8 million | $302.8 million | Up 19% |
| License revenue | $38.3 million | $32.1 million | Up 19% |
| Collaboration services revenue | $7.1 million | $13.6 million | Down 48% |
| Operating expenses | $380.0 million | $272.7 million | Up 39% |
| Income from operations | $28.8 million | $83.2 million | Down |
| Net income | $40.0 million | $68.6 million | Down 42% |
| Diluted EPS | $0.12 | $0.21 | Down |
| Operating cash flow | $84.4 million | $147.7 million | Down |
Gross margin was 96% in both periods. The lower operating and net income reflected sharply higher R&D and SG&A spending, partly offset by higher revenue and interest income. R&D rose 50% to $234.2 million, including a $35.0 million development milestone to Sairopa upon the ADU-1805 IND becoming effective. SG&A rose 28% to $131.4 million. Interest income increased to $19.5 million from $1.8 million, largely due to higher rates and investment balances.
Revenue growth was driven primarily by CABOMETYX: management attributed the increase to 10% more units sold and an 8% rise in average net selling price. Discounts and allowances also increased, with Medicare utilization cited as a factor. U.S. revenue was $367.4 million; Europe was $33.5 million and Japan $7.8 million.
Liquidity, cash flow and capital
At March 31, 2023, cash, cash equivalents, restricted cash equivalents and investments totaled $2.12 billion, compared with $2.07 billion at December 31, 2022. Working capital was $1.31 billion. Cash and cash equivalents on the balance sheet were $540.6 million; short- and long-term investments were $772.5 million and $806.6 million, respectively. Total liabilities were $588.2 million, including operating lease liabilities; the filing does not identify outstanding borrowings or provide a separate debt balance.
Operating cash flow was $84.4 million; investing activities used $49.6 million, including $36.5 million for acquired in-process R&D technology; financing activities provided $4.6 million. Operating cash flow declined year over year, principally because Q1 2022 included a $100.0 million Ipsen milestone collection and because operating cash payments increased. Management expects available cash and anticipated product and collaboration revenue to fund operations for at least 12 months and thereafter for the foreseeable future.
In March 2023, the board authorized repurchases of up to $550 million of common stock before year-end 2023. No shares were repurchased in Q1. The program is discretionary and may be changed or discontinued.
Outlook, developments and risks
- Management expects net product revenue may increase during the remainder of 2023, while discounts and allowances as a share of gross revenue may also rise. Collaboration services revenue may decline, primarily because of lower development-cost reimbursements.
- Management expects R&D and SG&A expenses to increase for the remainder of 2023, citing expanded trials, personnel, business development, commercial investment and organizational growth. It expects gross margin to remain broadly stable.
- CONTACT-03 did not meet its primary PFS endpoint; CONTACT-01 also failed its primary endpoint. COSMIC-313 met its PFS endpoint, but did not show a significant benefit at the interim OS analysis; another OS analysis was expected in the second half of 2023. The company said it would discuss a potential regulatory submission with FDA only if later OS results support it.
- CONTACT-02, evaluating cabozantinib plus atezolizumab in mCRPC, was expected to complete enrollment and report primary PFS results in the second half of 2023. Zanzalintinib phase 3 studies STELLAR-303 and STELLAR-304 were underway. The company also described ongoing development of XB002 and other pipeline assets.
- Generic-entry litigation is material to CABOMETYX. In MSN I, the court set no earlier than August 14, 2026 for potential FDA approval of MSN’s ANDA; separate MSN II litigation remained pending, with trial scheduled for October 2023. Teva proceedings were stayed, and the Cipla case was administratively closed after a stay. The company stated that early generic competition could materially harm U.S. CABOMETYX revenue and that loss exposure could not be estimated.
- Other risks include drug-pricing and reimbursement changes, including the Inflation Reduction Act; clinical and regulatory uncertainty; competition; third-party manufacturing and supply-chain reliance; and potential delays or failures in pipeline development. The company also anticipated higher federal tax payments in 2023 following required tax amortization of R&D expenses.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied filing covers Q1 2023, not Q1 2022.
- Track CABOMETYX sales, pricing, unit growth and rebate/discount trends, which drive revenue and are exposed to reimbursement and generic-entry risks.
- Follow outcomes and timing of MSN II, Teva and Cipla patent proceedings and assess potential implications for CABOMETYX exclusivity.
- Monitor clinical and regulatory updates, particularly the next COSMIC-313 OS analysis, CONTACT-02 results and progress in zanzalintinib trials.
- Assess whether rising R&D and SG&A spending, potential milestone payments and the proposed share repurchases remain consistent with cash generation and management’s liquidity outlook.